Ad Industry Arbiter Asks Wright To Pare Down Foot Ulcer Claims
This article was originally published in The Gray Sheet
Executive Summary
The investigative arm of the advertising industry's self-regulation program is recommending that Wright Medical cease distributing promotional materials that compare its GraftJacket regenerative tissue product to FDA-approved medical devices for treating foot ulcers in diabetics
You may also be interested in...
Regulatory News In Brief
Industry and FDA prioritize 180-day PMA goal: FDA will prioritize its goal of making a decision within 180 days on 50% of PMAs and panel-track PMA supplements received in fiscal 2007, even if that means not meeting its 150-day cycle goal for PMAs, under a recent agreement with AdvaMed, the Medical Device Manufacturers Association and National Electrical Manufacturers Association. The 1agreement stems from a May 22 public hearing - mandated by MDUFMA - during which FDA indicated that it likely would not be able to reach its PMA stretch goal (i.e. the 180-day goal) in 2007 due to the time required to meet the major deficiency letter goal (i.e. the 150-day goal) (2"The Gray Sheet" May 29, 2006, p. 3). The agreement only relates to the review of non-expedited original PMAs, according to FDA...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.